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Abstract  
 
HPV subtypes (16, 18) are associated with the development of cervical cancer, with 
oncoproteins E6 and E7 responsible for pathogenesis. The goal of this study was to evaluate 
our ‘smart system’ technology platform for DNA vaccination against cervical cancer. The 
vaccination platform brings together two main components; a peptide RALA which 
condenses DNA into cationic nanoparticles (NPs), and a polymeric polyvinylpyrrolidone (PVP) 
microneedle (MN) patch for cutaneous delivery of the loaded NPs. RALA condensed E6/E7 
DNA into NPs not exceeding 100 nm in diameter, and afforded the DNA protection from 
degradation in PVP. Sera from mice vaccinated with MN/RALA-E6/E7 were richer in E6/E7-
specific IgGs, displayed a greater T-cell-mediated TC-1 cytotoxicity and contained more IFN-γ 
than sera from mice that received NPs intramuscularly. More importantly, MN/RALA-E6/E7 
delayed TC-1 tumour initiation in a prophylactic model, and slowed tumour growth in a 
therapeutic model of vaccination, and was more potent than intramuscular vaccination. 
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1. Background 
Cervical cancer is the second most common cancer in women with 90% of cervical cancers 
caused by high-risk HPV strains such as types 16 and 181. Recently, two licensed prophylactic 
HPV vaccines, Gardasil® and Cervarix® have demonstrated efficacy as preventative vaccines2, 
that act by producing antibodies against specific HPV serotypes3. However, issues include 
patient compliance and a lack of efficacy against established HPV infections. This is due to 
the fact that upon infection, the intracellular location of the virus confers resistance to 
antibody attack4. For this reason, the development of a therapeutic HPV vaccine to treat 
patients with established HPV infections is clearly an unmet need5.   
HPV early proteins, particularly E6 and E7 viral genes are candidate target antigens for 
therapeutic vaccination; responsible for malignant transformation and tumour growth6. The 
E6 and E7 viral proteins disrupt tumour suppressor functions of p53 and the retinoblastoma 
protein (pRb) respectively7. The E6 protein stimulates p53 degradation via cellular 
ubiquitination, which disrupts the control of cell cycle progression. While the E7 protein 
disturbs pRb, repressing regulation of replication-associated genes8. Several therapeutic 
vaccine applications for HPV-16 E6 and E7 have been studied in preclinical models over the 
past two decades9-12, with limited success 13.  
DNA vaccination has become an effective strategy for the development of therapeutics 
against many types of cancer, including breast, ovarian, prostate14, and cervical carcinoma15. 
Numerous DNA vaccines directed against either HPV16 E6 or E7 have been tested with 
promising results in murine models16-20. However, successful implementation of DNA-based 
vaccination strategies requires a robust gene delivery vehicle capable of penetrating plasma 
membranes, protecting the nucleic acid cargo from intercellular degradation and ensuring 
the delivery to the nucleus of the target cell21. There is also a need to deliver the DNA to 
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antigen presenting cells (APCs), so that the intracellular antigens are processed through both 
the MHC class I and II presentation pathways, ensuring a full complement of cellular and 
humoral immune responses22. We have bioengineered a novel 30 amino acid cationic 
peptide delivery sequences, termed RALA. RALA consists of arginine/alanine/leucine/alanine 
repeats, interacts with anionic nucleic acids via electrostatic interaction to form nanoscale 
cationic particles. Moreover, RALA’s hydrophobic and hydrophilic regions facilitate 
interaction with the lipid bilayers, enabling transport of DNA across cellular membranes, 
endosomal disruption enabling transport of DNA to the nucleus. We have previously 
reported RALA’s ability to evoke reporter transgene expression in vitro and in vivo23-24.   
An emerging strategy to intramuscular vaccination is to target the APC population residing in 
the dermis via different delivery methods such as electroporation, tattooing, or microneedle 
(MN) arrays. The advantages of MN technology include pain free administration, simplicity 
of use, lack of needle stick injury, patient compliance and low manufacturing costs25. MNs 
are designed to painlessly breach the skin’s stratum corneum (SC) barrier and dissolve upon 
contact with the skin’s interstitial fluid to release the cargo in the needle tips26, 27. Herein we 
build upon the delivery of DNA from this system28 and report for the first time on a 
functional HPV-16 E6/E7 DNA vaccine candidate. In this investigation RALA-E6/E7 NPs were 
loaded into soluble MN arrays, and we demonstrate how effective this unique technology 
platform is compared to injectable systems in vivo. 
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2. Methods 
2.1 Preparation of RALA-E6/E7 nanoparticles 
The RALA peptide (Biomatik, USA) was supplied as a desalted lyophilized powder, and 
reconstituted as described previously23. DNA encoding the HPV-16 E6 and E7 antigens was 
purchased from Addgene (USA). The expression vector p1321 vector contained the genes for 
HPV16 E6, or E7 or E6/E7, the β-actin promoter and an ampicillin selective marker. RALA-
E6/E7 NPs were prepared at N:P ratios (the molar ratio of positively charged nitrogen atoms 
in the peptide to negatively charged phosphates in the pDNA backbone) ranging from 1 to 
12 by adding appropriate volumes of peptide solution to 1 μg pDNA. RALA-E6/E7 NPs were 
incubated at 19°C for 30 min to allow the formation of the NPs.  
2.2 DNA neutralisation assay 
RALA-E6/E7 at N:P ratios 0.25–12 were electrophoresed through a 1% agarose gel (Life 
Technologies, UK) with Tris acetate running buffer at 80 V for 60 min, and gels were 
visualized using a Multispectrum Bioimaging System (UVP, UK).  
2.3 Particle size and zeta potential analysis 
RALA-E6/E7 NPs were prepared at N:P ratios 2-12. The particle size and zeta potential was 
measured using a Nano ZS Zetasizer and DTS software (Malvern Instruments, UK) at 25oC. 
Variations included size from 4-37oC and storage of NPs at RT up to 1 month. Each 
measurement (n=3) had 15 sub measurements.  
2.5 Serum stability study 
RALA-E6/E7 NPs were incubated for up to 6 h at 37°C in 10% fetal calf serum. Subsequently, 
Proteinase K (Sigma-Aldrich, UK) was added (1 mg/ml) to decomplex the pDNA from RALA 
and samples were electrophoresed.  
2.7 Heparin stability study 
DNA was labelled with Quant-iT™ PicoGreen® dsDNA reagent (Life Technologies, UK). 
Heparin sulfate (Sigma, UK) (10–20 U/mL) was added to the NPs and the dissociation 
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properties of the NPs were measured via fluorescence (FLUOstar OPTIMA; BMG LABTECH, 
USA) with an excitation wavelength of 480 nm and a detection wavelength of 520 nm.  
2.8 Transmission electron microscopy (TEM) 
RALA-E6/E7 NPs were prepared at a N:P ratio of 10 and loaded onto a Formvar/Carbon mesh 
grid (Agar Scientific, UK). The grid was dried overnight and stained for 5 min with 5% 
aqueous uranyl acetate at 19°C. The grid was imaged using a JEOL 100CXII transmission 
electron microscope at an accelerating voltage of 80 kV. 
2.9 Encapsulation assay  
RALA-E6/E7 NPs were prepared and Quant-iT™ PicoGreen® Reagent (Life Technologies, UK) 
was added to each sample. The percentage encapsulation was calculated relative to naked 
DNA controls. Sample fluorescence was analyzed as per 2.7.  
2.10 In vitro transfections 
NCTC-929 fibroblast cells (ATCC) were seeded, conditioned for 2 h in Opti-MEM (Gibco, UK), 
which was then supplemented with 50 μl RALA/pDNA NPs. For comparison, cells were also 
transfected with Lipofectamine 2000 or polyethylenimine (PEI) (Life Technologies, UK). After 
6 h the media was removed and replaced with serum-supplemented culture medium.  
2.11 Western blot analysis 
NCTC-929 cell lysates were collected with radio immune precipitation assay (RIPA) buffer to 
determine the level of HPV-16 E6 and HVP-16 E7 protein expression. Each sample (20 μg) 
was electrophoresed through a 4-12% sodium dodecyl (SDS)-polyacrylamide gel (Life 
Technologies, UK), transferred onto a nitrocellulose membrane (Hybond-C, Amersham; UK) 
and probed with HPV-16 E6 and HVP-16 E7 antibodies (Abcam; UK). GAPDH was used as a 
loading control (Sigma; UK). Levels of protein expression were assessed using an Immobilon 
western detection kit (Millipore; UK). X-ray films were scanned using benchtop UV 
transilluminators (UVP Products Ltd) and density was calculated using Image J 
(http://rsbweb.nih.gov/ij/) incorporating correction of loading controls.  
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2.12 Fabrication of polymeric MN arrays  
RALA-E6/E7 loaded MNs were prepared using the micro-moulding process illustrated in Fig. 
4a. A 40% stock solution of PVP (360 kDa) (Sigma; UK) was prepared 50:50 with NP solution. 
25 mg of the polymeric gel containing the NPs was weighed into the moulds and centrifuged 
to ensure the MN cavities were filled. A further 0.5 g of 20% PVP polymer was added to the 
moulds to form the baseplate to which the MNs are attached and centrifuged again. The 
arrays were left to dry at room temperature, and after 48 h, were manually released from 
the moulds and the polymeric sidewalls removed using a heated scalpel. Each MN array 
contained 361 (19x19) needles 600 μm high with base width of 300 μm and 300 μm 
interspacing.  
2.13 Measurement of MN height reduction  
To determine the axial force required for mechanical fracture of the MNs, the TA-XT2 
texture analyser (Stable Microsystems, UK) was employed. MN arrays were attached to the 
moveable cylindrical probe of the texture analyser. An axial compression load of 45 N was 
applied to the polymeric MN arrays29. The height of the MNs was measured using a digital 
microscope (GE-5 USB) at 180x magnification.  
2.14 Optical coherence tomography (OCT)  
Neonatal full thickness porcine skin was prepared and equilibrated in PBS for 30 min at 37°C 
to restore conditions resembling the in vivo state. The skin was then placed onto a sheet of 
dental wax for support with the SC side facing towards the environment. Manual application 
using the thumb for 30 sec was applied.  Images were taken every 5 min to monitor the MNs 
dissolution profile. Depth of insertion of the MNs into the skin was determined using Image J 
software. 
2.15 Measurement of MN Stability 
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The MN/RALA-E6/E7 vaccine was packed in air tight packing film in temperature controlled 
environments of 4.0 ± 1.0 °C, RT (20.0 ± 1.0 °C), and 37 ± 1.0 °C. After 28 days, MNs were 
dissolved in OptiMEM serum free media for 2 h and NCTC-929 cells were transfected (2.16).  
2.16 Cell viability analysis  
NCTC-929 cells were seeded for 24 h prior to the assay. Media were supplemented with 5, 
10 or 20 mg/mL of 20% polymer (PVP) and incubated for 24 h. 10% MTS reagent (Promega, 
UK) was added to the cell medium and incubated for a further 2 h. Absorbance was 
measured at 450 nm on an EL808 96-well plate reader (BioTek Instruments Inc, UK).  
2.17 Clonogenic Assay 
24 h post transfection, NCTC-929 cells were plated at a density of 200 and 500 cells per 
well. Plates were then incubated for 14 days at 37oC in 5% CO2/95% air and then colonies 
were ﬁxed and stained with 0.4% crystal violet in 70% methanol and counted manually.  
2.18 Quantification of DNA cargo delivered in vivo  
NP-loaded MNs were applied to the dorsal surface of C57BL/6 mice ears (Charles River, UK) 
for 5 min, followed by removal of the array and quantification of the DNA remaining in the 
array using Quant-iT™ PicoGreen® dsDNA reagent (Life Technologies, UK). The remaining 
array was dissolved in 5 mL Tris buffer (10 mM) for 1 h and 50 μL of 1 mg/mL Proteinase K 
was subsequently added and samples incubated at 37°C for 1 h. Sample fluorescence was 
analyzed as per 2.7. 
2.19 Immunization of mice  
The experimental protocols were compliant with the UK Scientific Act of 1986, project 
license 2794 and were approved by QUB ethics committee. C57BL/6 mice were immunized 
with approximately 50 μg of either naked DNA (HPV-16 E6E7) or RALA-E6/E7 NPs by either 
I.M. or MN application on mice ears. Vaccination was followed by a 2nd and 3rd booster 
immunizations every 2 weeks. MN arrays laden with NPs or DNA were manually inserted 
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onto the dorsal side of both ears. The MNs were held in place for at least 5 min, secured in 
place using surgical adhesive tape, and then removed 24 h following application.  
2.20 ELISA for detecting anti-E6/E7 antibodies 
An indirect ELISA was carried out after the 2nd and 3rd boosts to determine E6/E7 specific IgG 
antibodies in mice sera. A 96 well plate was coated with 100 µl of purified HPV-16 E7/E6 
peptides (Proimmune, UK) at 0.5 mg/ml and incubated at 4°C overnight. After washing the 
serum samples diluted in PBS (1:100) were added to the ELISA wells. The plate was 
incubated with a 1:2000 dilution of a goat anti-mouse IgG HRP-conjugated antibody (Sigma, 
UK) at RT for 1 h. An enzyme substrate (OPD, Sigma) was added for colour development and 
Immunoreactivity was detected with an ELISA plate reader at 450 nm. Quantification of IgG 
was performed using an Easy Titer IgG assay kit (Thermo scientific, UK).  
2.21 Cytotoxicity Assay 
Following the third immunization, the spleen from each mouse was aseptically removed, 
homogenized and re-suspended in RBC lysis buffer (Sigma, UK). T cells (used as the effecter 
cells) were co-cultured at a ratio of 10:1 with irradiated TC-1 cells (104 per well) (used as the 
target cells) in RPMI-1640 medium with 20 units of interleukin-2 (Peprotech, UK) in 24-well 
plates (Corning) at 37°C for 6 days. The TC-1 cells were kindly provided by Dr Wu (Johns 
Hopkins University). In vitro radiation experiments were performed using a 160 kVp x-ray 
source (Faxitron X-ray, USA) with a 0.8 mm filter. Viable T cells were seeded with non-
irradiated TC-1 cells in the ratios of 5:1 and 10:1, respectively, in an assay medium (1% BSA 
medium) in triplicate at 37°C for 5 h in 96-well plates. After 5 h, the supernatant of each 
sample was collected and TC-1 cytotoxicity was measured using a LDH cytotoxicity detection 
kit (Roche, UK).   
2.22 Interferon-ɣ assay 
After the third immunization, spleens were removed and T cells (used as the effecter cells) 
were co-cultured at a ratio of 10:1 with irradiated TC-1 cells (104 per well) (used as the 
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target cells), with 20 units of interleukin-2 (Peprotech, UK) in 24-well plates (Corning) at 37°C 
for 4 days. The supernatant (100 µl) of each sample was taken after removing any debris by 
centrifugation. Interferon-ɣ was detected using Interferon-ɣ ELISA kit (Peprotech, UK). 
2.23 Tumour prophylactic assay 
C57BL/6 mice (n=9 per group) were immunized as 2.19. One week after the last vaccination, 
mice were challenged with 1X105 TC-1 cells/mouse in PBS implanted i.d. on the rear dorsum. 
The mice were monitored for evidence of tumour growth by palpation and measurement 
three times a week.  
2.24 Tumour challenge assay 
C57BL/6 mice (n=9 per group) were injected i.d. on the rear dorsum with 1X105 TC-1 
cells/mouse. When tumours reached 50 mm3, mice were immunized with either 100 µg 
naked DNA (HPV-16 E6E7) or RALA-E6/E7 NPs by either I.M. or MN application on the ears. 
Vaccination was followed by 2nd and 3rd booster immunizations every 2 weeks. Tumour 
dimensions were measured three times per week. In both in vivo studies, tumour volume 
was calculated using the formula 
𝑉𝑉 = 43𝜋𝜋𝑟𝑟3 
Where r is half of the geometric mean diameter (GMD), calculated as  
 
√L*B*D3  
 
 
 
 
2.25 Statistical analysis  
All experiments has at least three independent replicates, and results are expressed as mean 
± standard error (SE). Significance of differences was calculated using the two-tailed 
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unpaired t-test with a p value of ≤ 0.05 considered significant. Statistical analyses of the 
survival curves were calculated using the log rank (Mantel-Cox) test with a p value of ≤ 0.05 
considered significant. Statistical analyses were performed using Prism 5.0 (GraphPad 
Software; CA).  
 
3. Results  
3.1 Characterization and stability of RALA-E6/E7 NPs  
Results indicated that the RALA-E6/E7 NPs were formed from N:P 1 onwards; RALA 
prevented electrophoretic migration of DNA through the gel (Fig. 1a). RALA-E6/E7 NPs had 
an average hydrodynamic size of approximately 61.8-99.5 nm across all N:P ratios with a 
polydispersity index (PDI) <0.4 indicating a relatively homogenous population. The zeta-
potential of the RALA-E6/E7 NPs was 20-30 mV from N:P 4 upwards (Fig. 1b). TEM imaging at 
N:P 10 also revealed a core radius of NPs of approximately 70.9 nm (Fig. 1c). Encapsulation 
values of >90% from N:P 4 upwards indicated efficient complexation (Fig. 1d).  
RALA-E6/E7 NPs remained stable at room temperature for up to 30 days and also over a 
range of temperatures (4-37oC) (Fig. 2a & b). Further investigations revealed that RALA 
preserved the integrity of the E6/E7 DNA in the presence of serum and after exposure to 
heparin (Fig. 2c & d). This confirms that the NPs could remain intact in the presence of 
simulated biological fluids. 
3.2 In vitro gene expression with RALA-E6/E7 NPs 
RALA-E6/E7 NPs successfully transfected NCTC-929 cells as demonstrated by over expression 
of both HPV-16 E6 and HPV-16 E7 antigens compared to untreated cells (Fig. 3a). Toxicity of 
RALA is considerably reduced at 8.9% compared to commercially available agents such as 
Lipofectamine 2000 (25.6%) and PEI (70%) (Fig. 3b). 
 
 12 
3.3 The RALA-E6/E7 NPs do not compromise the PVP matrix  
A single MN array contains 361 projections (Fig. 4a), resulting in approximately 5 mg of 20% 
PVP. Results indicated that 20% PVP caused no significant cellular toxicity. Following 
exposure to the highest concentration (20 mg/mL) of PVP for 24 h, the % cell viability was 
87.5% compared to untreated cells (p= 0.1597, using a one-tailed, unpaired t-test). 
Morphologically, 20 mg/ml-treated cells did not appear to differ from control cells (Fig. 4b).  
Axial fracture force tests determined the mechanical strength of the PVP polymeric MNs. 
Using manual force, a penetration depth of 90% of needle length was achieved, and the 
needles were not broken or deformed by the process (Fig. 4c). Importantly, MNs that were 
loaded with RALA/E6-E7 NPs were still able to penetrate the skin effectively, displaying 
similar insertion mechanics to ‘empty’ MNs (20% PVP only). Furthermore, after evaluation of 
in situ dissolution kinetics of the MNs, it was found that by 15 min, MNs had both lost their 
needle profile and efficiently dissolved within the skin layers (Fig. 4c). Further analysis of 
E6/E7 (DNA only) or RALA-E6/E7 NP-loaded MN array revealed that an application of 45 N 
force to MN tips resulted in modest 10.2% and 9.2% reduction in needle height respectively, 
which was not significantly different from empty MNs with 10.8% reduction in needle height 
(p= 0.7775 & 0.4150 for DNA and RALA/E6-E7 NPs loaded MNs compared to empty MNs).  
 
3.4 RALA-E6/E7 NP release and functionality following incorporation in PVP matrix 
NCTC-929 cells transfected with RALA-E6/E7 NPs liberated from the PVP MN matrix 
expressed the viral proteins, yet naked E6/E7 DNA released from the PVP matrix was unable 
to evoke protein expression (Fig. 5a) indicating that RALA is necessary for the functionality of 
the E6/E7 DNA within the PVP matrix. Furthermore, PVP did not compromise functionality of 
the NPs after 28 days storage with a significant increase in HPV-16 E6/E7 protein expression 
compared to untreated cells (Fig 5b). 
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For release experiments in vivo, MN arrays were fabricated to contain 36 µg total DNA; 
however not the entire DNA will be present in the final MN array. Of the 36 µg total DNA 
initially incorporated into MN arrays, 30.2 ± 1.29 µg could be detected upon re-dissolution 
of the arrays; of that, 20.7 µg was present in the arrays following removal of excess 
sidewalls. For this reason, we therefore determined 20.7 µg to be deliverable using our MN 
array. Following a 5 min application to mouse ears, MN arrays were found to retain 9.5 µg 
DNA, indicating that 11.4 µg had been delivered; additionally, following a 24 h application 
procedure, only 1.9 µg DNA was retained in the arrays, indicating that 91% of the was 
delivered during a 24 h application (Fig. 5b).  
3.5 MN/RALA-E6/E7 evokes a consistent humoral and cell-mediated immune response 
Following immunization (Fig. 6a), it was shown that the concentration of antibodies from the 
NP groups (either I.M. or MN) was 2x that of the control group (Fig. 6b). These results 
suggest DNA vaccination using our MN-NP system elicits a robust antigen-specific humoral 
immune response, facilitating immunogenic memory at levels comparable, and even 
superior, to those observed following I.M. injections.  
Cytotoxicity and interferon-γ assays were carried out to test the immune response 
generated by the killing of the HPV-16 oncogenic antigen expressing cells (TC-1) by the E6/E7 
plasmid. MN/RALA-E6/E7-vaccinated mice evoked a two-fold higher TC-1 cytotoxicity than 
control mice. Additionally the cytotoxicity was greater in MN/RALA-E6/E7-vaccinated mice 
than in any other treatment group (Fig. 7a), indicating a robust immune response from 
MN/RALA-E6/E7 immunization.  
The IFN-γ release assay demonstrates that when primed T cell-enriched splenocytes were 
cultured without TC-1 cells, the amount of interferon-γ secreted was almost undetectable 
(Fig. 7b). However, when the primed T cell-enriched splenocytes were co-cultured with TC-1 
cells, there was an increase in the amount of IFN-γ released by the T cell-enriched 
splenocytes; the most impressive release of IFN-γ was from the MN/RALA-E6/E7-vaccinated 
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mice, which was significantly higher than the degree of IFN-γ released by T cells from naïve 
mice (p= 0.035 for mice vaccinated with MN/RALA-E6/E7 compared to controls). This is 
indicative of a cytotoxic T cell-mediated immune response.  
3.6 MN/RALA-E6/E7 vaccination prevents the uptake of tumours and slows the growth of 
established tumours  
In the prophylactic study, tumours were palpable at seven days post-challenge (i.d.) in 
controls, however vaccinated groups remained tumour-free up to 10 days, with tumours 
undetectable in the MN/RALA-E6/E7 group until 16 days. At day 20 post-challenge, the GMD 
of the tumours of all control mice and the empty MN group reached the pre-determined 
ethical study endpoint. Furthermore the growth of the tumours in the MN/RALA-E6/E7 was 
significantly retarded compared to the controls (p= 0.002 using two-tailed unpaired t-test). 
Figure 8a shows that that 4 out of 9 (44%) mice challenged did not develop any tumours 
after vaccination with MN/RALA-E6/E7. Immunization with RALA-E6/E7 NPs via the I.M. 
route also completely inhibited tumour development in 2 out of 9 mice (22.2%), while naked 
DNA (HPV-16 E6E7) delivered either by I.M. or MN application showed lower survival (only 1 
out 9 mice survived).  
In the therapeutic arm of the study, we determined that MN/RALA-E6/E7 vaccination of 
mice with pre-existing tumours caused complete regression of tumours in 2/9 mice (2 mice 
were censored because of other causes but their GMDs were ˂ 12 mm). Whereas when mice 
were vaccinated using RALA-E6/E7 by the I.M. route or naked DNA in MN, complete 
regression was observed in only 11% of mice (1/9). None of the other vaccination strategies 
significantly altered tumour growth kinetics/mouse survival (Fig. 8b). Furthermore, a clear 
difference in the tumour volume was found for the tumour-bearing mice that followed 
MN/RALA-E6/E7 vs other vaccination strategies (p= 0.004 two-tailed unpaired t-test). For 
example, after 20 days, the mean tumour volume for mice vaccinated with MN/RALA-E6/E7 
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was 246 mm2 compared to 486.85, 503.13, and 633.2 mm2 for mice vaccinated with 
MN/E6/E7, RALA-E6/E7 I.M, and E6/E7 I.M respectively.  
4. Discussion  
In this study, we validated a new system for the delivery of a HPV DNA therapeutic vaccine, 
which overcomes both intracellular and extracellular barriers using RALA/E6-E7 NPs, loaded 
in a PVP-based MN platform. Immune responses can be augmented by utilising delivery 
systems to protect the DNA cargo and facilitate delivery to APCs30. For optimal cell uptake, 
NPs should be less than 150 nm in diameter, have sufficient cationic charge to prevent 
aggregation in order to bind to the negatively charged cell membrane23. In this study, RALA 
conferred ideal size and charge characteristics on the E6-E7 DNA to facilitate efficient 
cellular uptake and antigen expression.  
The increased incidence of APCs in the dermal region has garnered interest in 
transcutaneous DNA vaccine delivery. Lower numbers of APCs are associated with I.M. 
vaccination and so efficient drainage to lymph nodes is required for antigen presentation31.  
A number of in vivo studies have demonstrated that MN immunization elicits an efficient 
immune response32, 33. Naked DNA34, influenza35 and HPV virus-like particles (VLP) 36, have 
elicited both B- and T-cell immune responses after administration to the skin using MNs. 
Rapid dissolution of MN arrays in the skin could be advantageous for vaccination and PVP 
can be safely excreted through the kidneys within a few days32,37. In this study the MNs 
could penetrate skin effectively and more importantly, MN-NP arrays retained functionality 
following extended storage conditions. Results revealed efficient transfection with RALA/E6-
E7 NPs with no transfection with naked HPV-16 E6-E7 into the polymer suggesting that the 
RALA is essential to protect the DNA in polymeric MN system. Similar observations have 
been reported where poly(lactic-co-glycolic acid) (PLGA) dissolving MNs adversely affected 
the stability of naked pDNA, with a subsequent loss of bioactivity 38.  
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It has been reported that a low dose of HPV16 PsV-encapsidated DNA (0.3 μg) incorporated 
into MNs effectively produced neutralizing antibody response against HPV39. Therefore, the 
quantity of DNA (10 μg) that we can deliver via the ear pinna should be sufficient to evoke 
an immune response.  The ear pinna exhibits two layers of epidermis and dermis, separated 
by cartilage, thereby doubling the amount of professional APCs, which after appropriate 
activation, migrate to one major pinna draining lymph node, eliciting rapid immune 
response induction40.  Indeed humoral and cytotoxic T cell-mediated immune responses 
after intra ear pinna (i.e.) DNA vaccination have been ~10 times stronger than I.M. 
immunizations40, 41. Typical target cells include keratinocytes, Langerhans’ cells, and dermal 
dendritic cells (DCs). Once mature, DCs can migrate to local lymph nodes where antigens are 
presented to T cells and the initiation of a variety of immunological responses ensues. In our 
immune analysis, the best humoral immune responses were obtained with MN/RALA-E6/E7 
group where a titer of 50 μg/ml was induced after 5 weeks and sustained following 8 weeks 
of immunization. Although humoral responses are unlikely to mediate cervical cancer 
regression or elimination of infection directly, these responses do affirm the immunogenicity 
of MN/RALA-E6/E7-vaccine. The significant increase of HPV16 E6 and E7-specific T cell 
immunity was identified via cytotoxicity and interferon γ ELISA assay after vaccination. 
MN/RALA-E6/E7-vaccinated mice evoked a two-fold higher TC-1 cytotoxicity than control 
mice, and a significant target-cell lysis was observed even at low effector-to-target ratios. 
Primed T cells can respond quickly and strongly when they come in contact with antigens 
previously encountered, leading to large amount of interferon-γ secretion42. A significant 
release of interferon γ from MN/RALA-E6/E7 vaccinated mice confirmed the cytotoxic T cell-
mediated immune response, which suggests that MN/RALA-E6/E7 elicited antigen-specific 
cell mediated immune responses superior to those observed by I.M. injections.  
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Furthermore the MN/RALA-E6/E7 vaccine generated a potent prophylactic antitumor effect 
against cervical tumour development. In a therapeutic regimen MN/RALA-E6/E7 elicited 
both a reduction in tumour size and prolonged survival. MN administration of the NPs 
induced a greater anti-tumour effect than the i.m. route which could be attributed to 
targeting more APCs within the skin. Activation and subsequent maturation of APCs will 
induce CD+8 killer lymphocytes and tumour infiltration. Indeed, previous studies have 
shown that MN vaccination rapidly induces specific tumour infiltrating CD8+ T cells 43-44. In 
both arms of the study, administration of E6/E7 peptides had no effect on tumour survival. 
Poor immunogenicity of peptide-based vaccines is not uncommon as they are heavily 
affected by the restriction of MHC45.  However it is also recognized that DNA vaccines can 
have limited immunogenicity in animal models46. Therefore future studies could focus on the 
co-administration of adjuvants, such as the C-terminal fragment of glycoprotein 96 (gp96), 
to stimulate E7- specific immune responses47. The further advantage of our nano-technology 
is that a bi or trivalent strategy can be incorporated into the MN patch.  
 
In this study, we have demonstrated successful cutaneous delivery of a DNA vaccine via in 
vivo delivery of NPs, resulting in a robust antigen-specific immune response.  Furthermore, 
prophylactic vaccination using NP-loaded MNs protected against cervical tumour 
development, and delayed the progression of established cervical cancer xenografts. Such 
MN-based DNA vaccines do not require cold-chain storage thus reducing costs, and 
ultimately should improve patient compliance. The licensing of four DNA vaccines in the 
veterinary medicine field48  provides optimism that DNA vaccines may soon be approved for 
applications in humans49,50, and this study should represent an important breakthrough 
technology for antigen-associated cancers.  
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5. Figure Legends 
Fig. 1: Physiochemical Characterization of the RALA-E6/E7 NPs. A) Gel retardation assay of 
RALA-E6/E7 NPs over a range of N:P ratios (0-12). B) Particle size, zeta potential and 
polydispersity index of RALA-E6/E7 NPs at N:P ratios 2-12. C) TEM image of RALA-E6/E7 NPs 
N:P ratio of 10. D) Encapsulation assay of RALA-E6/E7 NPs at N:P ratios 2-12. (N= 3 ± SEM) 
 
Fig. 2: RALA-E6/E7 forms stable NPs. A) Size, zeta potential and polydispersity index of 
RALA-E6/E7 nanoparticles (N:P ratio 10) incubated at 19°C for up to 30 days. B) RALA-E6/E7 
nanoparticles are stable over a temperature range (4-37°C). C) Serum stability of RALA-E6/E7 
nanoparticles (N:P ratio 10) incubated in water 10% serum at 37˚C and decomplexed with 
Proteinase K. D) Heparin stability study. (N= 3 ± SEM) 
Fig. 3:  RALA successfully delivers the therapeutic DNA that encodes HPV-16 E6, HPV-16 E7, 
or HPV-16 E6/E7. A) E6/E7 protein expression in NCTC-929 fibroblast cells with RALA-E6/E7 
nanoparticles for 24 h.  B) Clonogenic cell survival. (N= 3 ± SEM) 
 
Fig. 4: RALA-E6/E7 MNs are mechanically strong and biocompatible with PVP matrix. a) 
Manufacture of the MN-RALA-E6/E7 vaccine patch. B) Cell viability of NCTC-929 fibroblast 
cells following 24 h exposure to PVP in vitro. C) OCT Image of the in vivo dissolution profile of 
MNs laden with RALA-E6/E7 NPs in porcine skin over a 15 min period; dashed line represents 
the level of the epidermis. Image is representative of 3 separate experiments. D) Percentage 
height reduction of PVP MN arrays with either no cargo, or loaded with either HPV-16 DNA 
or NPs. (N=3, mean ± SEM) 
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Fig. 5: RALA is essential for effective E6/E7 delivery from the optimal MNs. A) Functionality 
of RALA-E6/E7 following release from 20% PVP MNs. After 24 h samples were analyzed for 
protein expression by western blot. B) Quantification of HPV-16 E6/E7 DNA in MN arrays 5 
min and 24 h post application to C57BL/6 mouse ears. RALA-E6/E7-loaded MN arrays were 
formulated to contain 36 µg DNA. (N= 3 ± SEM) 
 
Fig. 6: MN-RALA-E6/E7 evokes a consistent humoral mediated immune response. A) 
Schematic representation of the MN-RALA-E6/E7 vaccine regimen. B) Detection of E6/E7 
specific IgG levels following 2nd and 3rd booster immunizations in C57BL/6 mice in vivo. 
Following each immunization, blood serum was isolated and IgG levels measured via ELISA. 
(N=4 ± SEM). 
 
Fig. 7: MN-RALA-E6/E7 produces cell-mediated immune response. A) The cytotoxicity of T 
cells against TC-1 cells. 5:1 and 10:1 ratios indicates the different ratios of the effector cells 
(T cells) to the target cells (TC-1). T cells obtained from treatment groups were cultured with 
irradiated TC-1 cells for 6 days, and were subsequently purified and incubated with healthy 
TC- 1 cells for 5 h. B) INF γ levels following 3 immunizations with the MN-RALA-E6/E7. 
Spleens from the mice were removed, T-cells isolated and co-cultured with irradiated TC-1 
for 4 days. Supernatants were collected and INF γ levels detected via a sandwich ELISA. (N=3 
± SEM) 
Fig. 8: MN-RALA-E6/E7 vaccination prevents the uptake of TC-1 tumours, and delays the 
progression of established tumours. A) Prophylactic Study - Mice underwent a prime-boost-
boost regimen before challenge with 1x105 TC-1 E6/E7-expressing tumour cells implanted 
intradermally on the rear dorsum (N=9). B) Therapeutic study – 1x105 TC-1 tumour cells 
were implanted intradermally on the rear dorsum of C57BL/6 mice. Once tumours reached 
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50 mm3, a prime-boost-boost vaccine regimen was implemented. Black arrows indicate the 
time of immunization.   
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